Toby A. Eyre

5.7k total citations
147 papers, 1.4k citations indexed

About

Toby A. Eyre is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Toby A. Eyre has authored 147 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 95 papers in Pathology and Forensic Medicine, 87 papers in Genetics and 56 papers in Oncology. Recurrent topics in Toby A. Eyre's work include Lymphoma Diagnosis and Treatment (95 papers), Chronic Lymphocytic Leukemia Research (83 papers) and Viral-associated cancers and disorders (26 papers). Toby A. Eyre is often cited by papers focused on Lymphoma Diagnosis and Treatment (95 papers), Chronic Lymphocytic Leukemia Research (83 papers) and Viral-associated cancers and disorders (26 papers). Toby A. Eyre collaborates with scholars based in United Kingdom, United States and Australia. Toby A. Eyre's co-authors include Graham P. Collins, Chan Y. Cheah, Anna Schuh, Kate Cwynarski, Christopher P. Fox, Michael Wang, Amy A. Kirkwood, Maité Cabes, Georgina Hall and John C. Riches and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Toby A. Eyre

131 papers receiving 1.4k citations

Peers

Toby A. Eyre
Celeste Bello United States
Eliza A. Hawkes Australia
Biljana Mihaljević Serbia
Hartmut Eimermacher Germany
Flavia Salvi Italy
G. Lepeu France
Ali Aldaoud Germany
Vincenzo Pavone Italy
Carin Backlin Sweden
Maura Brugiatelli Italy
Celeste Bello United States
Toby A. Eyre
Citations per year, relative to Toby A. Eyre Toby A. Eyre (= 1×) peers Celeste Bello

Countries citing papers authored by Toby A. Eyre

Since Specialization
Citations

This map shows the geographic impact of Toby A. Eyre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Toby A. Eyre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Toby A. Eyre more than expected).

Fields of papers citing papers by Toby A. Eyre

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Toby A. Eyre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Toby A. Eyre. The network helps show where Toby A. Eyre may publish in the future.

Co-authorship network of co-authors of Toby A. Eyre

This figure shows the co-authorship network connecting the top 25 collaborators of Toby A. Eyre. A scholar is included among the top collaborators of Toby A. Eyre based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Toby A. Eyre. Toby A. Eyre is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Walewska, Renata, Toby A. Eyre, Adrian Bloor, et al.. (2025). 2025 British Society for Haematology Guideline for the treatment of chronic lymphocytic leukaemia. British Journal of Haematology. 207(6). 2296–2313.
3.
Jain, Nitin, Toby A. Eyre, Katherine B. Winfree, et al.. (2025). Real-world outcomes after discontinuation of covalent BTK inhibitor-based therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia & lymphoma. 66(8). 1400–1412. 2 indexed citations
4.
Gouill, Steven Le, Virginie De Wilde, Toby A. Eyre, et al.. (2024). Ibrutinib, Venetoclax Plus CD20 Monoclonal Ab Provides Very High MRD Negativity in Previously Untreated MCL Patients, Initial Results of OASIS II, a Randomized Phase 2 Trial. Blood. 144(Supplement 1). 745–745. 1 indexed citations
5.
Tadmor, Tamar, Toby A. Eyre, Ohad Benjamini, et al.. (2024). BELLWAVE-011: Phase 3 randomized trial of nemtabrutinib versus ibrutinib or acalabrutinib in untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.. Journal of Clinical Oncology. 42(16_suppl). TPS7088–TPS7088. 3 indexed citations
6.
Kothari, Jaimal, Toby A. Eyre, Ali Rismani, et al.. (2024). PembroWM : A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's Macroglobulinaemia. British Journal of Haematology. 205(6). 2273–2281. 3 indexed citations
7.
Herling, Marco, Claire Dearden, Francesco Zaja, et al.. (2024). Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study. Blood Advances. 8(4). 842–845. 2 indexed citations
8.
Muehlenbein, Catherine E., Catherine C. Coombs, Nirav N. Shah, et al.. (2023). CT-166 Long-Term Safety With ≥12 Months of Pirtobrutinib in Relapsed/Refractory B-Cell Malignancies. Clinical Lymphoma Myeloma & Leukemia. 23. S520–S520. 1 indexed citations
9.
Eyre, Toby A., et al.. (2023). Complete response of mantle cell lymphoma with central nervous system involvement at diagnosis with acalabrutinib – Case report. SHILAP Revista de lepidopterología. 5(1). 238–241. 2 indexed citations
10.
Wilson, Matthew R., et al.. (2023). How I manage mantle cell lymphoma: indolent versus aggressive disease. British Journal of Haematology. 201(2). 185–198. 6 indexed citations
11.
Gormsen, Lars Christian, Lasse Hjort Jakobsen, Toby A. Eyre, et al.. (2023). The impact of CHOP versus bendamustine on bone mineral density in patients with indolent lymphoma enrolled in the GALLIUM study. British Journal of Haematology. 204(4). 1271–1278. 2 indexed citations
12.
Walewska, Renata, Toby A. Eyre, Sally F. Barrington, et al.. (2023). Guideline for the diagnosis and management of marginal zone lymphomas: A British Society of Haematology Guideline. British Journal of Haematology. 204(1). 86–107. 8 indexed citations
13.
Wang, Michael, Nirav N. Shah, Wojciech Jurczak, et al.. (2023). MCL-155 Pirtobrutinib in Covalent BTK Inhibitor Pre-Treated Mantle Cell Lymphoma: Updated Results and Subgroup Analysis from the Phase 1/2 BRUIN Study With >3 Years Follow-Up from Start of Enrollment. Clinical Lymphoma Myeloma & Leukemia. 23. S459–S459. 1 indexed citations
14.
Eyre, Toby A., Paw Jensen, Stephen Booth, & Tarec Christoffer El‐Galaly. (2022). Bone health and glucocorticoid‐containing lymphoma therapy — a review of risk factors and preventative measures. British Journal of Haematology. 198(3). 431–442. 7 indexed citations
15.
16.
17.
McCulloch, Rory, Carlo Visco, Rebecca Frewin, et al.. (2019). R-BAC Maintains High Response Rate in Mantle Cell Lymphoma Following Relapse on BTK Inhibitor Therapy. Blood. 134(Supplement_1). 3989–3989. 4 indexed citations
18.
19.
Eyre, Toby A. & T. Littlewood. (2013). Anaemia in congestive heart failure. British Journal of Hospital Medicine. 74(5). 252–257. 1 indexed citations
20.
Eyre, Toby A., Andrew J. King, & Graham P. Collins. (2013). Classical Hodgkin's lymphoma: past, present and future perspectives. British Journal of Hospital Medicine. 74(11). 612–618. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Celeste Bello Breakdown of academic impact, for papers by Eliza A. Hawkes Breakdown of academic impact, for papers by Biljana Mihaljević Breakdown of academic impact, for papers by Hartmut Eimermacher Breakdown of academic impact, for papers by Flavia Salvi Breakdown of academic impact, for papers by G. Lepeu Breakdown of academic impact, for papers by Ali Aldaoud Breakdown of academic impact, for papers by Vincenzo Pavone Breakdown of academic impact, for papers by Carin Backlin Breakdown of academic impact, for papers by Maura Brugiatelli
Rankless by CCL
2026